Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of 9 months of vitamin D supplementation on arterial stiffness and blood pressure in Graves' disease: a randomized clinical trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Interactions between hypothalamic pituitary thyroid axis and other pituitary dysfunctions

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. A randomized general population study of the effects of repeated health checks on incident diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Fracture risk in women with type II diabetes. Results from a historical cohort with fracture follow-up

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ecological momentary assessments (EMAs) did not improve responsiveness of patient-reported outcomes on quality of life

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effects of supplemental vitamin D on muscle performance and quality of life in Graves' disease. A randomized clinical trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Muscle Performance and Postural Stability Are Reduced in Patients with Newly Diagnosed Graves' Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Diana Grove-Laugesen
  • Sofie Malmstroem
  • Eva Ebbehoj
  • Anne Lene Riis
  • Torquil Watt
  • Klavs Würgler Hansen
  • Lars Rejnmark
Vis graf over relationer

PURPOSE: Risk of cardiovascular disease (CVD) is increased in Graves' disease (GD). CVD is predicted by increased pulse wave velocity (PWV) and blood pressure (BP). GD and these risk factors are all associated with lower levels of vitamin D. We aimed to assess the effect of supplemental vitamin D on PWV and BP in GD.

METHODS: In a double-blinded trial, newly diagnosed GD patients were randomized to vitamin D3 70 µg/day (n = 44) or placebo (n = 42) as add-on to anti-thyroid medication. At baseline, 3 and 9 months PWV, BP and wave analysis were performed in office and 24 h setting. Between-group differences in change at 9 months were analyzed using linear mixed modelling. In subanalysis, effect of intervention in regard to baseline vitamin D insufficiency (25(OH)D < 50 nmol/L) was investigated. (The DAGMAR study, clinicaltrials.gov ID NCT02384668).

RESULTS: PWV was unaffected by intervention in main analysis. However in the subanalysis, comparing the response to intervention in the vitamin D insufficient (n = 28) and the vitamin D replete patients, supplemental vitamin D induced a significant decrease in office PWV of 1.2 (95% CI: -2.3; -0.1) m/s compared to placebo. Of notice, baseline PWV was non-significantly higher among the vitamin D insufficient as compared to the replete participants. In response to vitamin D, office central systolic BP (-3.9 (95% CI: -7.5; -0.3) and brachial mean BP (-3.3 (95% CI: -6.5; -0.3) declined whereas 24 h measurements were unaffected.

CONCLUSIONS: High-dose vitamin D supplementation did not affect PWV. We observed significant reduction in office but not 24 h BP. Subanalysis showed a clinically relevant PWV reduction among vitamin D insufficient participants, although regression towards the mean might contribute to findings. Further studies on supplemental vitamin D in GD should focus on patients with vitamin D insufficiency.

OriginalsprogEngelsk
TidsskriftEndocrine
Vol/bind66
Udgave nummer2
Sider (fra-til)386-397
Antal sider12
ISSN1355-008X
DOI
StatusUdgivet - 6 jul. 2019

ID: 59438940